NEW YORK (TheStreet) -- Shares of Pfizer (PFE - Get Report) were gaining in mid-morning trade on Monday despite an FDA report released this morning scrutinizing the company's study of the side effects of Chantix, its smoking cessation treatment.
On Wednesday, the FDA will meet to discuss whether Pfizer can eliminate the boxed warning on Chantix mentioning neuropsychiatric effects like mood swings and suicidal thoughts, Bloomberg reports.
The FDA requested the trial on Chantix's side effects in 2008 and it has now been completed.
However, the FDA said that Pfizer's "ascertainment of the primary neuropsychiatric adverse event outcomes" could have impacted the interpretation of the trial's results, according to the report.
Pfizer did not properly utilize interview techniques, and the trial had "substantial variability" in how the adverse events were recorded as well as inconsistency in the handling of cases, the FDA said.
The FDA noted that these mishandlings "served to lower the overall number of primary outcome events" and could have led to biased results.
(Pfizer is held in the Dividend Stock Advisor portfolio. See all of the holdings with a free trial.)
Separately, TheStreet Ratings objectively rated this stock according to its "risk-adjusted" total return prospect over a 12-month investment horizon. Not based on the news in any given day, the rating may differ from Jim Cramer's view or that of this articles's author.
TheStreet Ratings rated this stock as a "buy" with a ratings score of B+.
The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, expanding profit margins and increase in stock price during the past year. We feel its strengths outweigh the fact that the company has had sub par growth in net income.
You can view the full analysis from the report here: PFE